At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 53 enrolled
Drug / intervention
Elpipodect +1 moredrug
Likely dose
Elpipodect 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, PK and the Effect of MK-8189 on QTc in Participants With Schizophrenia
In Brief
A Phase 1 clinical trial evaluating Elpipodect and Placebo for Schizophrenia. Completed, enrolled 53 participants across 3 sites.
Detailed Summary
The primary purpose of this study is to assess the safety and tolerability of multiple ascending doses of elpipodect in participants with schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartJul 2022
Primary CompletionFeb 2023
TodayJul 2026
First PostedJun 6, 2022
Enrollment StartJul 12, 2022
Primary CompletionFeb 24, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.1 years ago
Interventions
Elpipodectdrug
MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.
Placebodrug
MK-8189 dose-matching placebo tablets will be administered orally QD.